



Better Health for a Better World

Mylan in India

Creating better health for a better world. That's what inspires Mylan to provide high quality medicine to the world's 7 billion people.

Our Mission

At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:

- Innovate to satisfy unmet needs
- Make reliability and service excellence a habit
- Do what's right, not what's easy
- Impact the future through passionate global leadership

Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic and over-the-counter remedies. We market our products in more than 165 countries and territories. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world.

Mylan's history in India began in 2007 with the acquisition of Matrix Laboratories Limited. The deal transformed Mylan overnight into one of the world's largest manufacturers of active pharmaceutical ingredients (API) and allowed us to vertically integrate the production of our oral solid dosage (OSD) medicines.

Today, Mylan has 47 manufacturing facilities, 19 of which are located in India. Those 19 facilities include eight API facilities, six OSD facilities and five Injectables facilities, which manufacture our high quality medicines for markets all over the world. Our manufacturing capabilities in India include a range of dosage forms, such as tablets, capsules and injectables, in a wide variety of therapeutic categories.

While Mylan has grown significantly in recent years, the company and its workforce remain committed to delivering high quality medicine.

Our commercial businesses, based in India, market high quality API to third parties around the world and antiretroviral (ARV) products for people living with HIV/AIDS. In fact, more than 50% of our API manufacturing capacity is dedicated to ARVs, all of which are manufactured in India.

In addition, Mylan also markets products in Critical Care, Virology, Onco Care, and Women's Health therapeutic areas in India.

Mylan's presence in India also includes one of Mylan's two state-of-the-art R&D centers of excellence located in Hyderabad. The center is fully integrated with the company's global R&D function, with a unique and efficient, round-the-clock research, development, clinical and regulatory capability.



Better Health
for a Better World



Fast Facts

India workforce:

Approximately 15,000

Products:

A global market portfolio of more than 7,500 marketed products, including nearly 75 that are marketed in India

ARV access globally:

- 40% of all people on treatment for HIV worldwide, depend on a Mylan antiretroviral every day
- Brought cost of ARV therapy down from \$10,000 per patient per year to less than \$100 per patient per year^[1]

ARV access in India:

- Leading ARV supplier selected by India's National AIDS Control Organization (NACO) since 2012

Manufacturing presence:

India: 19 units (8 API, 6 OSD, 5 INJ)

Global: 47 facilities

Patent applications^[2]:

India: Filed 536 | Granted 46

US: Filed 75 | Granted 49

EU: Filed 49 | Granted 21

Others: Filed 42 | Granted 07

API, OSD and Injectable manufacturing capacity in India:

API capacity: >4800 KL

OSD capacity: 27 billion doses

Injectable capacity: ~375 million

Regulatory track record:

17 of Mylan's facilities in India (5 OSD, 8 API, 4 Injectables) are approved by the U.S. Food and Drug Administration

R&D capabilities:

Employ roughly 3,000 regulatory professionals and scientists globally, nearly half of which are based in India, with focus on API, OSD, Injectables and biosimilars, as well as clinical research to develop and validate bioanalytical methods

Mylan's ranking in Indian pharma market: 59^[3]

Commercial Businesses and Therapy Areas



Virology

Hepatitis, HIV, Tuberculosis, Dermatology and Transplants



Oncology

Biosimilars, Cytotoxics



Critical Care

Antifungals, Antibiotics



Women's Health

Infertility, Contraception, Wellness

Doing Good & Doing Well



In 2017, Mylan's interventions in healthcare, education and community welfare positively impacted -

- more than 350,000 people through disease awareness programs across seven states
- more than 12,000 students by providing infrastructure to schools through classrooms and toilets

We also addressed access to clean drinking water, sanitation and waste management in rural communities.

As part of our environmental commitment, we helped clean two major water bodies and planted 22,000 trees in Andhra Pradesh in 2017.

Sustainability










At Mylan, we invest and innovate to achieve resource efficiency, enhance environmental stewardship, preserve the communities in which we operate and find ways to improve our environmental performance.

100% of Mylan's wastewater generated in our Hyderabad manufacturing sites utilizes Zero Liquid Discharge (ZLD) technology, eliminating any discharge to the environment. Today, Mylan operates 11 ZLD facilities across India.

We conduct environmentally responsible operations that allow us to satisfy the needs of our global business.

- Eight of Mylan's API sites are ISO 140001 certified for environmental management systems
- Seven of Mylan's API sites are ISO 50001 certified for energy-management systems.

Nearly 60 Years of Unconventional Success

1961	1966	1973	1989	2002	2007	2008	2012	2013	2015	2016	2017
		FINGERPRINT 1961-2006			FOOTPRINT 2007-2011				BLUEPRINT 2012-TODAY		
											
FOUNDED IN WEST VIRGINIA	FIRST FDA APPROVAL	MYLAN GOES PUBLIC	BLOWING THE WHISTLE	COURY BECOMES VICE CHAIRMAN AND CEO	MYLAN GOES GLOBAL MALIK JOINS	\$ 5B IN REVENUE	BRESCH NAMED CEO	GLOBAL INJECTABLES	Famy Care Ltd. BROADER REACH	DERMATOLOGY AND TOPICALS LEADER MEDA Strength and Diversity	BIOSIMILARS GROWTH

Leadership Team



Heather Bresch
Chief Executive Officer



Rajiv Malik
President



Dr. Hari Babu Bodepudi
Chief Operating Officer



Sanjeev Sethi
Chief Scientific Officer



Rakesh Bamzai
President, India
and Emerging Markets

Corporate Offices in India:

Mylan Laboratories Limited
Platina – 3, Prestige Technology Park
Sarjapur Outer Ring Road
Bangalore – 560103
+91 80 66728001

Mylan Laboratories Limited
Plot No 564/A/22
Road No 92, Jubilee Hills
Hyderabad – 500034
+91 40 30866666 / 6444

Media Relations:

communications.india@mylan.in

Stay Connected:

Mylan.in
Mylan.com

[LinkedIn](#)

[YouTube](#)

[@MylanNews](#)
[@MylanCareers](#)



Mylan.in